Rationale for the review: COVID-19 treatment can worsen parasitic disease in patients with coinfection. Consequently, there is a need to investigate the infection with SARS CoV 2 and Strongyloides. We aim to systematically review clinical and laboratory features of COVID 19 and Strongyloides coinfection, to investigate possible interventions and outcomes in this pathology. Also, we aim to identify difficulties in managing the parasitic disease manifestations in this context and to emphasize research gaps requiring further attention. Methods: We will search two electronic databases (LitCOVID, and WHO COVID 19) and will include studies on SARS CoV 2 and Strongyloides coinfection. We will adapt the WHO UMC system for standardized case causality assessment to evaluate if using corticosteroids or other immunosuppressive drugs in COVID 19 patients determined acute strongyloidiasis manifestations. Expected results: We will present the evidence in three distinct packages: study description, methodological quality assessment and data extracted. We will summarize the evidence and will draw conclusions as to the quality of the evidence.
Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created enormous medical and economic burdens on human society. However, the co-existence of COVID-19 and diseases in tropical regions is not taken seriously. To improve the understanding of the current status and trends on crosstalk of COVID-19 and tropical diseases, this paper provided an analysis, from a bibliometric perspective, of the COVID-19-related publications in ″Tropical Medicine″-entitled journals. Methods: We used Clarivate Analytics and VOSviewer to analyze 783 publications in seven ″ Tropical Medicine″-entitled journals. Document overview, basic bibliometric characteristics, citation performance, co-authorship, co-citation, bibliographic coupling, and co-occurrence of keywords and terms were summarized in this article. Results: Document overview revealed that 76.12% of the related publications were published in open access mode, and basic bibliometric characteristics indicated that the year 2021 was the peak of the number of publications, the documents in the seven journals were unevenly distributed, and ″ article″ was the main publication type. The citation performance analysis elucidated that the documents of interest were frequently cited. The co-authorship analysis showed cooperation networks on the level of region, organization and author. General knowledge of COVID-19 was the overlap of co-citation and bibliographic coupling behavior. Finally, the co-occurrence of keywords and terms revealed the current and emerging hotspots. Conclusions: The main current research focuses in ″Tropical Medicine″-entitled journals are the clinical features of COVID-19 patients, and the emerging trends are the hesitancy in making vaccines against SARS-CoV-2 and the circumstance where COVID-19 coexisted with tropical diseases. In summary, this bibliometric analysis of COVID-19-related studies in seven ″Tropical Medicine″-entitled journals highlights the current research focuses of this field to inspire future studies.
While the development of different vaccines has slowed the dissemination of SARS-CoV-2, the occurrence of breakthrough infections continues to fuel the pandemic. As a strategy to secure at least partial protection, with a single dose of a given COVID-19 vaccine to maximum possible fraction of the population, delayed administration of subsequent doses (or boosters) has been implemented in many countries. However, waning immunity and emergence of new variants of SARS-CoV-2 suggest that such measures may jeopardize the attainment of herd immunity due to intermittent lapses in protection. Optimizing vaccine dosing schedules could thus make the difference between periodic occurrence of breakthrough infections or effective control of the pandemic. To this end, we have developed a mechanistic mathematical model of adaptive immune response to vaccines and demonstrated its applicability to COVID-19 mRNA vaccines as a proof-of-concept for future outbreaks. The model was thoroughly calibrated against multiple clinical datasets involving immune response to SARS-CoV-2 infection and mRNA vaccines in healthy and immunocompromised subjects (cancer patients undergoing therapy); the model showed robust clinical validation by accurately predicting neutralizing antibody kinetics, a correlate of vaccine-induced protection, in response to multiple doses of mRNA vaccines. Importantly, we estimated population vulnerability to breakthrough infections and predicted tailored vaccination dosing schedules to maximize protection and thus minimize breakthrough infections, based on the immune status of a sub-population. We have identified a critical waiting window for cancer patients (or, immunocompromised subjects) to allow recovery of the immune system (particularly CD4+ T-cells) for effective differentiation of B-cells to produce neutralizing antibodies and thus achieve optimal vaccine efficacy against variants of concern, especially between the first and second doses. Also, we have obtained optimized dosing schedules for subsequent doses in healthy and immunocompromised subjects, which vary from the CDC-recommended schedules, to minimize breakthrough infections. The developed modeling tool is based on generalized adaptive immune response to antigens and can thus be leveraged to guide vaccine dosing schedules during future outbreaks.
Animal to human transmission of SARS-CoV-2 has not previously been reported in a zoo setting. A vaccinated African lion with physical limitations requiring hand feeding tested positive for SARS-CoV-2 after development of respiratory signs. Zoo employees were screened, monitored prospectively for development of symptoms, then re-screened as indicated, with confirmation by RT-PCR and whole-genome virus sequencing when possible. Trace-back investigation narrowed the source of infection to one of five people. Three exposed employees subsequently developed symptoms, two with viral genomes identical to the lion9s. Forward contact tracing investigation confirmed probable lion-to-human transmission. Close contact with large cats is a risk factor for bidirectional zoonotic SARS-CoV-2 transmission that should be considered when occupational health and biosecurity practices at zoos are designed and implemented. SARS-CoV-2 rapid testing and detection methods in big cats and other susceptible animals should be developed and validated to facilitate timely implementation of One Health investigations.
The dynamics of innate and adaptive immunity to infection in infants remain obscure. Here, we used a multi-omics approach to perform a longitudinal analysis of immunity to SARS-CoV-2 infection in infants and young children in the first weeks and months of life by analyzing blood samples collected before, during, and after infection with Omicron and Non-Omicron variants. Infection stimulated robust antibody titers that, unlike in adults, were stably maintained for >300 days. Antigen-specific memory B cell (MCB) responses were durable for 150 days but waned thereafter. Somatic hypermutation of V-genes in MCB accumulated progressively over 9 months. The innate response was characterized by upregulation of activation markers on blood innate cells, and a plasma cytokine profile distinct from that seen in adults, with no inflammatory cytokines, but an early and transient accumulation of chemokines (CXCL10, IL8, IL-18R1, CSF-1, CX3CL1), and type I IFN. The latter was strongly correlated with viral load, and expression of interferon-stimulated genes (ISGs) in myeloid cells measured by single-cell transcriptomics. Consistent with this, single-cell ATAC-seq revealed enhanced accessibility of chromatic loci targeted by interferon regulatory factors (IRFs) and reduced accessibility of AP-1 targeted loci, as well as traces of epigenetic imprinting in monocytes, during convalescence. Together, these data provide the first snapshot of immunity to infection during the initial weeks and months of life.
Africa has a dual burden of disease, which causes preventable morbidities and fatalities. This is a result of our healthcare system9s deficiencies, which has suffered a serious decline since the COVID-19 pandemic. However, this opened up the possibilities for digital health interventions, which innovators could utilize to provide solutions to these public health issues. Health hackathons, which offer an environment for innovators to brainstorm and collaborate, are rare in Africa. This paper outlines the planning and execution of a virtual hackathon and explores its implications for the promotion of public health in Africa. Over the course of a month, we collaborated with innovation hubs in Africa to hold an open call, a training session, a design sprint, as well as a 48-hour virtual hackathon. We received 68 submissions from 13 African nations. Following the selection of 10 teams, design thinking was employed to develop solutions to a public health problem in Africa. The theme for the hackathon was 9Promoting Health Equity with Digital Technology in Africa9 and areas of focus were non-communicable diseases; infectious disease epidemiology and surveillance; and health information and data management. All ten teams developed prototypes, the top three teams were offered the opportunity to continue on to the startup accelerator program, while the winning team also received a cash prize. In conclusion, the public health hackathon challenged African medical students to develop innovations to healthcare problems. There is need for further study to evaluate the solutions developed.
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine - Condition: COVID-19
Intervention: Biological: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
Sponsors: Wuhan BravoVax Co., Ltd.; National University Hospital, Singapore; Shanghai BravoBio Co., Ltd.
Not yet recruiting
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care - Condition: COVID-19
Intervention: Drug: Plitidepsin
Sponsor: PharmaMar
Not yet recruiting
Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers - Condition: COVID-19
Interventions: Biological: Corfluvec component 1 low dose; Biological: Corfluvec component 2 low dose; Biological: Corfluvec component 1 high dose; Biological: Corfluvec component 2 high dose; Biological: Corfluvec low dose; Biological: Corfluvec high dose; Biological: Placebo
Sponsors: Tatyana Zubkova; MDP-CRO, LLC; St. Petersburg State Pavlov Medical University
Active, not recruiting
COVID-19 Self-testing Study - Condition: COVID-19
Intervention: Behavioral: SMARTest mobile app for COVID-19 self-testing
Sponsor: Columbia University
Recruiting
A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection - Condition: COVID-19
Interventions: Drug: Azvudine; Drug: Nirmatrelvir-Ritonavir
Sponsors: Shandong Provincial Hospital; Central hospital Affiliated to Shandong First Medical University; The Second Affiliated Hospital of Shandong First Medical University; The Affiliated Hospital Of Southwest Medical University; Gansu Provincial Hospital
Not yet recruiting
A Chatbot to Enhance COVID-19 Knowledge - Condition: COVID-19
Interventions: Device: chatbot; Other: Printed educational booklet
Sponsor: Sun Yat-sen University
Not yet recruiting
Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia - Condition: COVID-19 Pneumonia
Intervention: Radiation: Low-Dose Radiation Therapy
Sponsors: Jiangsu Cancer Institute & Hospital; Nanjing Chest Hospital; The Affiliated BenQ Hospital of Nanjing Medical University; Central South University; Zhongda Hospital
Not yet recruiting
Tetrandrine Tablets Used in Hospitalized Adults With COVID-19 - Condition: COVID-19
Intervention: Drug: Tetrandrine
Sponsor: Peking University Third Hospital
Not yet recruiting
INFLUENCE OF HIGH FREQUENCY CHEST WALL OSCILLATION IN HOSPITALIZED PATIENTS WITH COVID-19 - Condition: COVID-19
Intervention: Device: HIGH FREQUENCY CHEST WALL OSCILLATION
Sponsor: Cairo University
Not yet recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19 - Condition: COVID-19
Interventions: Drug: QLS1128; Drug: Placebo
Sponsor: Qilu Pharmaceutical Co., Ltd.
Recruiting
Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients. - Conditions: Vitamin C; COVID-19 Pneumonia
Interventions: Drug: Vitamin C; Drug: Placebo
Sponsor: Zhujiang Hospital
Recruiting
Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness - Condition: COVID-19 Respiratory Infection
Interventions: Drug: Azvudine; Drug: Placebo
Sponsor: Peking Union Medical College Hospital
Not yet recruiting
UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia - Conditions: Mesenchymal Stem Cell; COVID-19 Pneumonia
Intervention: Biological: UC-MSCs treatment
Sponsors: Shanghai East Hospital; Sir Run Run Shaw Hospital
Recruiting
The Difference Between Non-invasive High-frequency Oscillatory Ventilation and Non-invasive Continuous Airway Pressure Ventilation in COVID-19 With Acute Hypoxemia - Conditions: COVID-19 Pneumonia; Non-invasive Ventilation
Interventions: Device: Non-invasive high-frequency oscillatory ventilation; Device: Non-invasive continuous positive airway pressure ventilation
Sponsor: Guangzhou Institute of Respiratory Disease
Not yet recruiting
Safety and Efficacy of the Therapy With BREINMAX® for the Treatment of Patients With Asthenia After COVID-19 - Conditions: Asthenia; COVID-19
Interventions: Drug: Ethyl methyl hydroxypyridine succinate + Meldonium; Drug: Placebo
Sponsor: Promomed, LLC
Completed
Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination - CONCLUSIONS: The findings of the current study are important because they help to identify COVID-19 treatments that are efficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategy for COVID-19 that could be used in conjunction with pharmacological agents.
The Potential of Vouacapanes from Pterodon emarginatus Vogel Against COVID-19 Cytokine Storm - Purpose: The emergence of the COVID-19 pandemic has led to the search for potential therapeutic responses for various aspects of this disease. Fruits of Pterodon emarginatus Vogel (Fabaceae), sucupira, have been used in Brazilian traditional medicine because of their anti-inflammatory properties, which have been proven in vivo, in vitro, and in silico. Therefore, the aim of this work is to evaluate P. emarginatus oleoresin and isolated diterpenes by in vitro anti-inflammatory models. Methods: In…
Bafilomycin A1 inhibits SARS-CoV-2 infection in a human lung xenograft mouse model - Coronavirus disease 2019 is a global pandemic caused by SARS-CoV-2. The emergence of its variant strains has posed a considerable challenge to clinical treatment. Therefore, drugs capable of inhibiting SARS-CoV-2 infection, regardless of virus variations, are in urgently need. Our results showed that the endosomal acidification inhibitor, Bafilomycin A1 (Baf-A1), had an inhibitory effect on the viral RNA synthesis of SARS-CoV-2, and its Beta and Delta variants at the concentration of 500 nM….
The impact of neutrophil extracellular traps in coronavirus disease - 2019 pathophysiology - Coronavirus disease 2019 (COVID-19), which is caused by novel coronavirus-2019 (nCoV-2019), is a highly contagious disease with high mortality and morbidity risk. Infected people may suffer from respiratory infections, which may be more progressive in patients with a defective immune system and underlying medical problems. In this regard, the cells involved in the innate immune system, play a decisive role in disease progression and complication development. Pathogen entrapment is the critical…
Traditional herbal compounds as candidates to inhibit the SARS-CoV-2 main protease: an in silico study - COVID-19, a disease caused by the SARS-CoV-2 virus, is responsible for a pandemic since March 2020 and it has no cure. Therefore, herein, different theoretical methods were used to obtain potential candidates from herbal compounds to inhibit the SARS-CoV-2 main protease (M^(pro)). Initially, the 16 best-scored compounds were selected from a library containing 4066 ligands using virtual screening by molecular docking. Among them, six molecules (physalin B 5,6-epoxide (PHY), methyl amentoflavone…
Minimalist Nanocomplex with Dual Regulation of Endothelial Function and Inflammation for Targeted Therapy of Inflammatory Vascular Diseases - Vascular disorders, characterized by vascular endothelial dysfunction combined with inflammation, are correlated with numerous fatal diseases, such as coronavirus disease-19 and atherosclerosis. Achieving vascular normalization is an urgent problem that must be solved when treating inflammatory vascular diseases. Inspired by the vascular regulatory versatility of nitric oxide (NO) produced by endothelial nitric oxide synthase (eNOS) catalyzing l-arginine (l-Arg), the eNOS-activating effects of…
A Series of Adenosine Analogs as the First Efficacious Anti-SARS-CoV-2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study - Given the rapid progression of the coronavirus disease 2019 (COVID-19) pandemic, an ultrafast response was urgently required to handle this major public crisis. To contain the pandemic, investments are required to develop diagnostic tests, prophylactic vaccines, and novel therapies. Lately, nucleoside analog (NA) antivirals topped the scene as top options for the treatment of COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Meanwhile, the continuous…
The impact of loneliness on compliance with COVID-19 prevention guidelines - Many individuals have been reluctant to follow the COVID-19 prevention guidelines (e.g., wearing a mask, physical distancing, and vigilant handwashing) set forth by the U.S. Center for Disease Control to reduce the spread of COVID-19. In this research, we use reciprocal altruism theory to investigate the role of loneliness and its impact on compliance with these guidelines. Our findings indicate that lonely individuals are less willing to comply with COVID-19 prevention guidelines than…
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV - CONCLUSIONS: The mRNA vaccination against SARS-CoV-2 elicits humoral and B cell responses quantitatively similar between PLWHIV and HCs, but there are important differences in terms of antibody functionality and phenotypes of memory B cells, reinforcing the notion that tailored vaccination policies should be considered for these patients.
Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. The identification of effective antiviral drugs remains an urgent medical need. In this context, here we report 17 new 1,4-benzopyrone derivatives, which have been designed, synthesized, and characterized for their ability to block the RNA-dependent RNA polymerase (RdRp) enzyme, a promising target for antiviral drug discovery. This compound series represents a good starting point for developing…
Broadly neutralizing aptamers to SARS-CoV-2: a diverse panel of modified DNA antiviral agents - Since its discovery COVID-19 has rapidly spread across the globe with a massive toll on human health with infection mortality rates as high as 10% and a crippling impact on the world economy. Despite numerous advances there remains an urgent need for accurate and rapid point-of-care diagnostic tests, and better therapeutic treatment options. To contribute chemically distinct, non-protein-based affinity reagents, we report here the identification of modified DNA-based aptamers that selectively…
Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection - The COVID-19 pandemic has posed a severe threat to human life and the global economy. Although conventional treatments, including vaccines, antibodies, and small-molecule inhibitors, have been broadly developed, they usually fall behind the constant mutation of SARS-CoV-2, due to the long screening process and high production cost. Functional nucleic acid (FNA)-based therapeutics are a newly emerging promising means against COVID-19, considering their timely adaption to different mutants and…
Protein post-translational modification in SARS-CoV-2 and host interaction - SARS-CoV-2 can cause lung diseases, such as pneumonia and acute respiratory distress syndrome, and multi-system dysfunction. Post-translational modifications (PTMs) related to SARS-CoV-2 are conservative and pathogenic, and the common PTMs are glycosylation, phosphorylation, and acylation. The glycosylation of SARS-CoV-2 mainly occurs on spike (S) protein, which mediates the entry of the virus into cells through interaction with angiotensin-converting enzyme 2. SARS-CoV-2 utilizes glycans to…
Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity - Recent studies have shown that RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro), and papain-like protease (PLpro) are necessary for SARS-CoV-2 replication. Among these three enzymes, PLpro exhibits both proteolytic and deubiquitinase (DUB) activity and is responsible for disrupting the host’s innate immune response against SARS-CoV-2. Because of this unique property of PLpro, we investigated the inhibitory effects of phytochemicals on the SARS-CoV-2 PLpro enzyme. Our…
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial - Background: Quercetin, a natural polyphenol with demonstrated broad-spectrum antiviral, anti-inflammatory, and antioxidant properties, has been proposed as an adjuvant for early-stage coronavirus disease 2019 (COVID-19) infection. Objective: To explore the possible therapeutic effect of quercetin in outpatients with early-stage mild to moderate symptoms of COVID-19. Methods: This was an open-label randomized controlled clinical trial conducted at the department of medicine, King Edward Medical…